Enforced miR-509 expression in decreased proportion of cells in S-phase, induced apoptosis and activated caspase-3/7. by Yee Sun Tan (176098)

Decrease in total RNA after enzymes treatment in culture supernatant samples. by Gilberto Gutiérrez García (9611388)

Incorporating a social responsibility goal in the prompt causes overleverage in utilities (A) and decreases risk of low ESG rating (B) (Study 3). by Philipp Winder (21615570)

Diabetic <i>TauT</i>-deficient mice showed kidney hypertrophy and decreased survival rate. by Xiaobin Han (608327)

Distinct effects on calcium channel activation of <i>CACNA1I</i> disease-associated amino acid substitutions A398E/V and M1425V/I. by Yousra El Ghaleb (22075892)

Subjects:

Increased AHP Amplitude and decreased AP firing in the presence of kainic acid is dependent on the GluR5 subunit. by Barbara Gisabella (330774)

Fig 5 - by Melissa A. Hill (13170105)

Mice exposed to neonatal hyperoxia have persistent RVH and decreased vessel density at 21d. by Marta Perez (526067)

Metformin pre-administration decreases the oxidative stress, retains antioxidant effect and decreases apoptosis in colon and lung tissues in mice irradiated with GCRsim. by Silvia Siteni (10344070)

Decreases in CAPs. by Enrico Amico (527269)

“…<p>This figure shows the local decreases in co-activation from wakefulness to unconsciousness, using the same t-contrast as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0100012#pone.0100012-Boveroux1" target="_blank">[7]</a>. …”

Influence of ghrelin treatment (0.5 μg/g BW, twice a day, intraperitoneal (ip.)) on bacterial load after cecal ligation and puncture (CLP)-induced sepsis. by Daniel Siegl (717509)

Influence of ghrelin treatment (0.5 μg/g BW, twice a day, intraperitoneal (ip.)) on inflammatory mediators after cecal ligation and puncture (CLP)-induced sepsis. by Daniel Siegl (717509)

The blood plasma, kidney, and brain concentration levels (ng/ml) of GSK360A presented for 5 and 24 hours after GSK360A (30 mg/kg) was administered orally by gavage. by Jin Zhou (90734)

Phenethyl isothiocyanate activates leptin signaling and decreases food intake by Miho Yagi (5921252)

“…Leptin is a weight-reducing hormone produced by adipose tissue, which decreases food intake <i>via</i> hypothalamic leptin receptors (Ob-Rb) and the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway. …”

List of Included studies. by Zahra Tajik (20752452)

“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

KRAP−/− Mice Showed Decreased Weight-Gain and Decreased Adiposity. by Takahiro Fujimoto (268158)

Specific inhibition of ATG5 and ATG7 decrease low glucose-induced LC3-II accumulation. by Delphine Balmer (458897)

“…<p>Lentiviruses expressing specific shRNA were used to decrease the expression of ATG5 and ATG7 as described in material & methods, then each clonal cell colony was treated and cultured as mentioned in material & methods. …”